Management of Albuminuria in Hypertensive Diabetics
NCT01907958 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 280
Last updated 2013-07-25
Summary
Multicenter stepped wedge cluster randomized trial of family practice clinics in Quebec and Ontario comparing the effect of introducing a Point of Care testing (POCT) for urine albumin to usual practice on quality of care in hypertensive patients with Type 2 diabetes.
Conditions
- Microalbuminuria
- Hypertension
- Type 2 Diabetes
Sponsors & Collaborators
-
Medpharmgene, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-04-30
- Primary Completion
- 2014-06-30
- Completion
- 2014-06-30
Countries
- Canada
Study Locations
More Related Trials
-
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
NCT02040441 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
NCT06190158 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Eplerenone, ACE Inhibition and Albuminuria
NCT00315016 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus
NCT00136773 ·Status: COMPLETED ·Phase: PHASE4
-
Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01853553 ·Status: COMPLETED ·Phase: PHASE3
-
TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension
NCT05268926 ·Status: TERMINATED ·Phase: PHASE2
-
REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study
NCT06108427 ·Status: RECRUITING ·Phase: NA
-
High Dose Ace Inhibitor Therapy Versus Combination of ACE and ARB Therapy
NCT00212901 ·Status: COMPLETED ·Phase: NA
-
The Effect of Amiloride and Spironolactone in Healthy Persons
NCT00857909 ·Status: COMPLETED ·Phase: PHASE1
-
The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables
NCT01195805 ·Status: COMPLETED ·Phase: NA
-
Bosentan Use in Patients With Diabetic Nephropathy
NCT00638131 ·Status: TERMINATED ·Phase: PHASE3
-
Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus
NCT02046395 ·Status: COMPLETED ·Phase: PHASE4
-
Dietary Intervention in ADPKD on Tolvaptan
NCT03858439 ·Status: COMPLETED ·Phase: NA
-
Urinary Biomarkers of the Progression of Alport Kidney Disease
NCT01705132 ·Status: COMPLETED
-
Human Urine Sample Collection for Alport Nephropathy Biomarker Studies
NCT01602835 ·Status: TERMINATED
-
Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT01336972 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal
NCT01930370 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)
NCT00890279 ·Status: UNKNOWN ·Phase: PHASE2
-
Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
NCT03596957 ·Status: UNKNOWN ·Phase: PHASE4
-
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
NCT01918488 ·Status: UNKNOWN ·Phase: NA
-
Dial-Bicarb Trial: Effects of a Lower vs. Higher Concentration of Dialysate Bicarbonate
NCT06270134 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus
NCT00367978 ·Status: COMPLETED ·Phase: PHASE4
-
Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial
NCT02055872 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
NCT01500590 ·Status: UNKNOWN ·Phase: PHASE4
-
EMPRA (EMPagliflozin and RAs in Kidney Disease)
NCT03078101 ·Status: COMPLETED ·Phase: PHASE2